Sutro Biopharma, Inc.
STRO
$20.48
-$0.83-3.90%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 45.70M | 99.61M | 102.48M | 105.65M | 104.47M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.70M | 99.61M | 102.48M | 105.65M | 104.47M |
| Cost of Revenue | 144.74M | 151.37M | 166.42M | 200.81M | 223.07M |
| Gross Profit | -99.04M | -51.77M | -63.93M | -95.17M | -118.59M |
| SG&A Expenses | 32.82M | 35.33M | 41.02M | 41.39M | 46.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 177.56M | 186.70M | 207.44M | 242.20M | 270.04M |
| Operating Income | -131.86M | -87.10M | -104.95M | -136.55M | -165.57M |
| Income Before Tax | -180.73M | -153.72M | -191.18M | -214.42M | -206.35M |
| Income Tax Expenses | -96.00K | -115.00K | -93.00K | 2.34M | 2.34M |
| Earnings from Continuing Operations | -180.64 | -153.60 | -191.09 | -216.77 | -208.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -180.64M | -153.60M | -191.09M | -216.77M | -208.70M |
| EBIT | -131.86M | -87.10M | -104.95M | -136.55M | -165.57M |
| EBITDA | -125.80M | -80.39M | -97.63M | -128.99M | -158.10M |
| EPS Basic | -17.32 | -16.35 | -22.49 | -25.69 | -24.94 |
| Normalized Basic EPS | -9.80 | -7.85 | -10.12 | -12.25 | -14.29 |
| EPS Diluted | -17.32 | -16.35 | -22.49 | -25.69 | -24.94 |
| Normalized Diluted EPS | -9.80 | -7.85 | -10.12 | -12.25 | -14.29 |
| Average Basic Shares Outstanding | 46.87M | 38.82M | 34.10M | 33.83M | 33.55M |
| Average Diluted Shares Outstanding | 46.87M | 38.82M | 34.10M | 33.83M | 33.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |